D-0502 — Investigational Agent
Selective Estrogen Receptor Degrader · Phase 1 · Inventisbio
Mechanism of Action
D-0502 is an orally bioavailable selective estrogen receptor degrader and antagonist that binds ERalpha, blocking transcriptional activity and inducing receptor degradation, including in ESR1-mutant tumors.
Investigational Indications
- ER-positive/HER2-negative advanced or metastatic breast cancer